ArticleCommunications medicine2026
Machine learning-based proteogenomic data modeling identifies circulating plasma biomarkers for early detection of lung cancer.
Article in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CEACAM5 as a biomarker of semi-solid, lepidic lung adenocarcinoma.Translational lung cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGenetic aberrations are among the critical driving factors of lung cancer. Importantly, the impact of genetic variations on proteomic dysregulations with the goal of characterizing potential diagnostic biomarkers at the population-level requires additional investigation. Modeling such proteogenomic interactions is crucial in understanding early-stage biological disruptions to inform biomarker discovery, successful clinical trials, and developing effective therapeutics.
methodsWe investigated two complementary aspects of lung cancer risk. First, we performed a genome-wide association study of lung cancer using population-scale datasets, then examined whether lung cancer risk-associated variants influence plasma protein levels using the UK Biobank Pharma Proteomics Project data. Second, we identified plasma proteomic dysregulations in presymptomatic and symptomatic patients with the objective of pinpointing diagnostic biomarkers through leveraging machine learning methods.
resultsUsing the identified proteins, machine learning models achieved median cross-validated AUCs of 0.85-0.88 (0-4 years before diagnosis [YBD]), 0.81-0.84 (5-9 YBD), and 0.80-0.86 (0-9 YBD). Performing survival analyses within the 5-9 YBD group, elevated levels of eight proteins, such as CALCB, PLAUR, and CD74, were found to significantly associate with lower survival. We identified 22 disease-associated proteins, of which 14 have been previously implicated in lung cancer, including CEACAM5, CXCL17, GDF15, WFDC2 along with 8 novel proteins. These proteins were enriched in pathways related to cytokine signaling, interleukin regulation, neutrophil degranulation, and lung fibrosis.
conclusionsWhile these findings do not establish mechanistic causality, they highlight proteomic alterations reflecting systemic changes preceding the diagnosis. Our study contributes to understanding genome-proteome relationships in lung cancer and identifies circulating proteins warranting further investigation as potential early biomarkers for screening and risk stratification.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.